Literature DB >> 8248556

Rates of local control, metastasis, and overall survival in patients with posterior uveal melanomas treated with ruthenium-106 plaques.

M Kleineidam1, R Guthoff, S M Bentzen.   

Abstract

The prognostic importance of clinically assessed tumor variables, patient variables, and treatment variables of 184 patients treated with ruthenium-106 eye plaques for uveal melanoma was studied using crude survival, metastatic disease and local tumor control as the endpoints. Using the multivariate Cox proportional hazards model, tumor diameter, age and sex were identified as the strongest variables predicting survival. Risk of metastasis was found to be dependent on tumor size (diameter) only and the metastasis was generally observed within 6 years after the end of treatment (96%). Clinically diagnosed local tumor control was predicted by tumor T-stage, treatment time, and total dose to the sclera. No correlation between metastatic disease and local failure was detected.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8248556     DOI: 10.1016/0167-8140(93)90007-u

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  6 in total

1.  Surgery vs. radiotherapy in patients with uveal melanoma : Analysis of the SEER database using propensity score matching and weighting.

Authors:  Bum-Sup Jang; Ji Hyun Chang; Sohee Oh; Yu Jin Lim; Il Han Kim
Journal:  Strahlenther Onkol       Date:  2017-09-06       Impact factor: 3.621

2.  Monte Carlo Simulation of the Treatment of Eye Tumors with (106)Ru Plaques: A Study on Maximum Tumor Height and Eccentric Placement.

Authors:  Lorenzo Brualla; Francisco J Zaragoza; Wolfgang Sauerwein
Journal:  Ocul Oncol Pathol       Date:  2014-05-07

Review 3.  Brachytherapy for patients with uveal melanoma: historical perspectives and future treatment directions.

Authors:  Beatrice Y Brewington; Yusra F Shao; Fredrick H Davidorf; Colleen M Cebulla
Journal:  Clin Ophthalmol       Date:  2018-05-17

Review 4.  Efficacy and complications of ruthenium-106 brachytherapy for uveal melanoma: a systematic review and meta-analysis.

Authors:  Saeed Karimi; Amir Arabi; Zahra Siavashpour; Toktam Shahraki; Iman Ansari
Journal:  J Contemp Brachytherapy       Date:  2021-05-18

5.  Atypical Presentation: Metastatic Uveal Melanoma in a Young Patient without Visual Complaints.

Authors:  Pedro Grachinski Buiar; Sérgio Jobim de Azevedo
Journal:  Front Oncol       Date:  2017-05-18       Impact factor: 6.244

6.  Long-Term Outcomes in Uveal Melanoma After Ruthenium-106 Brachytherapy.

Authors:  Gilda Cennamo; Daniela Montorio; Luca D' Andrea; Antonio Farella; Elide Matano; Mario Giuliano; Raffaele Liuzzi; Maria Angelica Breve; Sabino De Placido; Giovanni Cennamo
Journal:  Front Oncol       Date:  2022-01-03       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.